OSTEOARTHRITIS (MB GOLDRING, SECTION EDITOR)

Current Rheumatology Reports

, 15:385

Open Access This content is freely available online to anyone, anywhere at any time.

The Future of Osteoarthritis Therapeutics: Emerging Biological Therapy

  • A. MobasheriAffiliated withD-BOARD European Consortium for Biomarker Discovery, Faculty of Medicine and Health Sciences, The University of NottinghamArthritis Research UK Centre for Sport, Exercise and Osteoarthritis, The University of NottinghamArthritis Research UK Pain Centre, The University of NottinghamMedical Research Council and Arthritis Research UK Centre for Musculoskeletal Ageing Research, The University of NottinghamMedical Research Council and Arthritis Research UK Centre for Musculoskeletal Ageing Research, The University of BirminghamCenter of Excellence in Genomic Medicine Research (CEGMR), King Fahad Medical Research Center (KFMRC), King AbdulAziz UniversityMusculoskeletal Research Group, School of Veterinary Medicine and Science, Faculty of Medicine and Health Sciences, The University of NottinghamSchools of Pharmacy and Life Sciences, University of Bradford Email author 

Abstract

Biological therapy is a thriving area of research and development, and is well established for chronic forms of rheumatoid arthritis (RA) and ankylosing spondylitis (AS). However, there is no clinically validated biological therapy for osteoarthritis (OA). Chronic forms of OA are increasingly viewed as an inflammatory disease. OA was largely regarded as a “wear and tear disease”. However, the disease is now believed to involve “low grade” inflammation and the growth of blood vessels and nerves from the subchondral bone into articular cartilage. This realization has focused research effort on the development and evaluation of biological therapy that targets proinflammatory mediators, angiogenic factors and cytokines in articular cartilage, subchondral bone and synovium in chronic forms of OA. This review article provides an overview of emerging biological therapy for OA, and discusses recent molecular targets implicated in angiogenesis and neurogenesis and progress with antibody-based therapy, calcitonin, and kartogenin, the small molecule stimulator of chondrogenesis.

Keywords

Osteoarthritis Therapeutics Biological therapy Therapeutic antibodies Calcitonin Kartogenin Fibroblast growth factor 18 (FGF-18) Anticytokine therapy Angiogenesis Neurogenesis DMOADs DMARDs